Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
141
resultados
Última actualización
06/05/2026 [08:25:00]
Resultados 25 a 50 de 141
Resumen de: US20260108568A1
0000 Provided are a Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease and a use thereof, and the Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease is named as Bifidobacterium longum subsp. infantis BI03 strain, with a deposit number of CGMCC No. 24473 and deposit date of Mar. 7, 2022. The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.
Resumen de: US20260108494A1
0000 The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) wherein each symbol is as defined in the description or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.
0000
Resumen de: AU2024357688A1
This invention relates to the treatment of a neuropsychiatric disorder, such as schizophrenia or Parkinson's disease, by administration (for example, transdermally) of tilivapram, zatolmilast, roflumilast, or a pharmaceutically acceptable salt thereof.
Resumen de: WO2026082154A1
Deposition of N-terminally truncated and pyroglutamate-modified Abeta peptides (AβpE3) play an important role in the aggregation of the amyloid-β (Aβ) protein in the brain. The N-terminally truncated and pyroglutamate-modified Abeta peptides, therefore, can be a suitable target for the prevention and treatment of Alzheimer's Disease (AD). Disclosed herein are antibodies and fragments having excellent specificity to N-terminally truncated and pyroglutamate-modified Abeta peptides, as well as uses of these antibodies and fragments for the prevention and treatment of AD.
Resumen de: EP4729620A1
Provided are a gene therapy vector for treating Parkinson's disease and a use thereof. Specifically, provided is an adeno-associated virus (AAV) vector for treating Parkinson's disease, which can simultaneously express functional tyrosine hydroxylase (TH), GTP-cyclohydrolase 1 (GCH1) and aromatic amino acid decarboxylase (AADC) to promote dopamine synthesis. Also provided are an AAV virus particle containing the AAV vector, a composition containing the AAV vector or the AAV virus particle, and uses of the AAV vector, the AAV virus particle and the composition in the preparation of drugs for preventing or treating Parkinson's disease.
Resumen de: WO2024260959A1
The present invention relates to an improved process for preparing optically active secondary amines, or a pharmaceutically or veterinary acceptable salt thereof, in high yield and high purity involving (2-naphthoyl)-L-proline as chiral resolving agent. The invention also relates to the use of (2-naphthoyl)-L-proline as chiral resolving agent of secondary amines, preferably of amine compounds of formula (I), wherein R1 is H, C1- C4 alkyl, preferably R1 is methyl; and R2 is C1-C4 alkyl, preferably R2 is n-propyl and the use of the obtained optically amine compounds of formula (IV) for the preparation of rotigotine.
Resumen de: GB2701173A
A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is independently selected from: halo, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -O-C1-C6 alkyl and -SO2-C1-C6 alkyl; R2 is independently selected from: H, halo, and -CN; R3 is selected from: halo, and -O-C1-C6 alkyl; R4 is independently selected from: halo, -CN, C1-C6 alkyl, -O-C1-C6 alkyl, C3-C6 cycloalkyl, -O-C3-C6 cycloalkyl, and -O-C1-C6 alkyl-C3-C6 cycloalkyl; wherein said C1-C6 alkyl, -O-C1-C6 alkyl, C3-C6 cycloalkyl, -O-C3-C6 cycloalkyl, and -O-C1-C6 alkyl-C3-C6 cycloalkyl, are each independently optionally substituted with from 1 to 6 groups selected from: deuterium, -CN, halo, -O-C1-C3 alkyl, and -O-C1-C3 haloalkyl; R5 is selected from: H, halo, and -O-C1-C6 alkyl; X1 is CR6; and R6 is independently selected from: H, halo, C1-C6 alkyl, C1-C6 haloalkyl, -O-C1-C6 alkyl, and -O-C1-C6 haloalkyl. The compounds are GPR17 modulators. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases and conditions associated with GPR17, including multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). Figure formula (I)
Resumen de: WO2026077862A1
The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.
Resumen de: WO2026079761A1
The present invention relates to a composition for alleviating, preventing, or treating Alzheimer's disease, the composition comprising apigenin and oxyresveratrol. A composition according to the present invention is highly effective in reducing Alzheimer's disease pathology caused by β-amyloid, which is increased by aging and oxidative stress, and improving β-amyloid-induced memory loss and cognitive function.
Resumen de: WO2026080811A1
Provided are methods and compositions for treating Parkinson's disease (PD). The compositions inhibit the expression or activity of adenosylmethionine decarboxylase 1 (AMD1).
Resumen de: WO2026077485A1
The present invention relates to an application of a DFNA5/GSDME inhibitor in preparing a drug for treating Alzheimer's disease. Also provided is an application of a specific DFNA5 gene knockdown system in preparing a drug for treating Alzheimer's disease. The present invention demonstrates that in reactive astrocytes of patients with Alzheimer's disease, the mRNA expression level of GSDME is significantly high, and GSDME can be used as an effective target for Alzheimer's disease. Provided is an application of a reagent, which specifically inhibits GSDME gene expression in astrocytes, in preparing a drug for treating Alzheimer's disease, so as to develop a novel treatment drug for Alzheimer's disease. The present invention demonstrates that the reagent, which inhibits GSDME gene expression, can be used for preparing a drug for treating Alzheimer's disease. The present invention also provides a theoretical basis for clinical treatment of Alzheimer's disease.
Resumen de: WO2026078185A1
The present invention relates to a composition comprising a c-AMP Response Element-Binding protein 3 (CREB3), in particular a variant of CREB3 protein, or a nucleic acid molecule encoding said CREB3 protein or said variant of CREB3 protein, for use as a medicament, in particular for treating or preventing diseases associated with a degeneration of motor neurons. The present invention further relates to CREB3 protein, in particular said variant of CREB3 protein, as a biomarker for the stratification or the prognosis of patients suffering, or susceptible of suffering, from a disease associated with a degeneration of motor neurons.
Resumen de: WO2026077305A1
Provided are a method and a drug combination for preventing or treating neurodegenerative diseases, comprising a pharmaceutical composition and a combination drug product. The drug combination, the pharmaceutical composition, and the combination drug product can be used to treat and/or prevent neurodegenerative diseases in patients, preferably neurodegenerative diseases associated with α-synuclein aggregation, and more preferably Parkinson's disease.
Resumen de: WO2026076481A1
The present disclosure related generally to polynucleotide sequences encoding an antigen-binding construct capable of specifically binding to intracellular tau, and uses thereof, in particular for the treatment of tauopathies, including Alzheimer's Disease.
Resumen de: WO2026076634A1
Provided are Aβ375 related oligomers/aggregates in human brains and anti-Aβ3175 related oligomers/aggregates antibodies thereof. In addition, the using of anti-Aβ3175 related oligomers/aggregates antibodies for the treatment of Alzheimer's disease (AD) is also provided.
Resumen de: WO2026080717A1
Methods and compositions for treating or reducing the development of neurodegenerative diseases.
Resumen de: WO2026077393A1
The present invention belongs to the field of biopharmaceuticals. Disclosed are a Muse cell-derived protein complex, a preparation method therefor, and use thereof. The composition of the protein complex is: a stem cell lysate of Muse cells after being cultured in a stress environment for a predetermined time, or a protein complex obtained by separating and purifying the stem cell lysate. The protein complex has a good cell damage repair effect, especially a strong ability to repair nerve cell damage, and is expected to be used for treating neurodegenerative diseases, cerebral stroke, cerebrovascular disease, arthritis, enteritis, recovery after trauma, autism, depression, and pulmonary fibrosis. In particular, the neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and different types of spinocerebellar ataxia (SCA).
Resumen de: US20260103474A1
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US20260103445A1
The present invention relates to compositions comprising an RXR agonist, an RAR agonist, or a dual RXR/RAR agonist. The present invention further relates to methods of using the agonist compositions for treating or preventing dementia and cancer. In some embodiments, the dementia comprises Alzheimer's disease. In some embodiments, the cancer comprises leukemia.
Resumen de: AU2024354107A1
Provided are an siRNA inhibiting the expression of an amyloid precursor protein (APP) gene in a human cell, a polypeptide-oligonucleotide drug, and a use. The siRNA has good APP expression inhibitory activity, and a suitable modification is made to the siRNA to improve the silencing capability against a target and reduce off-target activity. The siRNA and a conjugate thereof are expected to be applied for clinically preventing and treating an APP target-related disease such as cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).
Resumen de: WO2026077192A1
Provided in the present invention are preparation and use of a novel MAO-B inhibitor containing a tetralin-1-amine structure, which belong to the field of medicines. The derivative is a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The compound of the present invention can be used for inhibiting monoamine oxidase (MAO), especially selectively inhibiting MAO-B. The compound can be used for treating diseases such as Parkinson's disease, Alzheimer's disease, and emotional disorders, and exhibits good application prospects.
Resumen de: WO2026077861A1
The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.
Resumen de: EP4725499A1
The present invention is related to the biomedical and biopharmaceutical sectors. Specifically, it refers to a chimeric antigen comprising the combination of the amino and carboxyl terminal regions of the amyloid beta peptide (Aβ), the amino and carboxyl terminal regions of the tau protein and a T cell epitope. The pharmaceutical composition comprising this chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant increases the efficacy of immunotherapy for the prevention and treatment of Alzheimer's Disease (AD). The chimeric antigen exerts its action by stimulating a multitarget humoral response with high titers of anti-Aβ and anti-tau antibodies simultaneously. This favors the combined elimination of toxic species of both Aβ and tau from the brain, which prevents or significantly improves the clinical symptoms and neuropathology of AD.
Resumen de: EP4725321A1
0001 The present invention provides a medical food composition comprising at least one probiotic and optionally one or more amino acids. The composition is useful in patients with Parkinson's disease to enhance the systemic stability and central bioavailability of levodopa (L-DOPA). It exerts effects by modulating gut microbiota, reinforcing intestinal barrier integrity, and reducing systemic inflammation and oxidative stress, thereby improving motor and non-motor symptoms and minimizing L-DOPA-induced long-term side effects such as dyskinesia.
Nº publicación: EP4725497A1 15/04/2026
Solicitante:
GEMVAX & KAEL CO LTD [KR]
Resumen de: EP4725497A1
The present invention relates to a pharmaceutical composition for use in preventing or treating periodontal disease, or atherosclerosis or Alzheimer's disease caused by periodontal disease, more particularly, a pharmaceutical composition comprising a peptide having the amino acid sequence of SEQ ID NO: 1 to prevent or treat the periodontal disease or the atherosclerosis or Alzheimer's disease caused by periodontal disease, so that it is effective in suppressing osteoclastogenesis, suppressing Porphyromonas gingivalis colony formation, and suppressing gingipain expression. Further, the pharmaceutical composition is safe to a living body and involves less side effects including abnormal response.
BOPI
Sede Electrónica
